Lipiodol-based anti-tumour emulsion for treating cancer
US10064883B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2013 |
| Grant date | Sep 4, 2018 |
| Priority date | — |
| Expiry date | Jan 27, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumor activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.